- Home
- ACRS vs AVTX Comparison
ACRS vs AVTX Comparison
Compare ACRS & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRS | AVTX |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 982.5M |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ACRS | AVTX |
|---|---|---|
| Price | $6.28 | $19.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $10.20 | ★ $40.57 |
| AVG Volume (30 Days) | ★ 1.9M | 727.7K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 69.01 | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | $1,683,000.00 | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $1.74 | $8.65 |
| 52 Week High | $6.52 | $24.27 |
Technical Indicators
Market Signals| Indicator | ACRS | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 54.97 |
| Support Level | $4.13 | $17.40 |
| Resistance Level | $6.52 | $20.68 |
| Average True Range (ATR) | 0.36 | 1.08 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 83.72 | 63.61 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.